Biograph mct 64 pet ct scanner

To reduce the mutual interference of the two radiotracers, imaging was carried out at different days. The median 6.5 (range 1.0–34.0) days passed from 18F-PSMA-1007 to 18F-FDG. Patients fasted for at least 6 h prior to injection of the 18F-FDG and blood sugar level is lower than 15 mg/L. The injected activity of 18F-FDG were mean 388 ± 55 MBq (range 281–503 MBq) and scanning was performed 60 min after injection, while the injected activity of 18F-PSMA-1007 were 348 ± 52 MBq (range 266–458 MBq), and according to Giesel et al. (5 (link)) imaging began 180 min after injection. All scans were obtained on a Biograph mCT-64 PET/CT scanner (Siemens). Non-enhanced low-dose (1.3–1.5 mSv) CT scan was performed with CT parameters (140 keV, 42 mA) section width of 8 mm, pitch of 0.8, and CT datas were used for attenuation correction. The PET-scan, PET was acquired in 3-D FlowMotion with an acquisition time of 2 min per bed position. Both scans was performed from vertex to the mid-thigh. Images were reconstructed with an ordered-subset expectation-maximization iterative reconstruction algorithm (three iterations, 21 subsets).

Imaging equipment: German Siemens Biograph mCT (64) PET/CT scanner. Image acquisition: the patients were required to fast for 4–6 h before examination, and the height, weight, and blood sugar on the day of examination were recorded; PET/CT whole-body imaging was performed 1 h after the imaging agent (¹⁸F-FDG, 3.70–5.55 MBq/kg) injection, and was imaged first with low-dose CT and then PET scan. PET imaging was performed at 2 min/bed, about six to seven beds per patient according to their heights. The TrueX + TOF (ultraHD-PET) method was used for image reconstruction, with two iterations and 21 subsets; the matrix was 200 × 200, and the image acquisition mode was 3D. The post-processing workstation TrueD system (Siemens) was used for image evaluation (lung window width 1,200 HU, window level −600 HU, mediastinal window width 350 HU, window level 40 HU).
Then, the HRCT scan was performed on the GGN site under a breath-hold condition. The collection and reconstruction conditions were as follows: the tube voltage was 140 kV, and the tube current was automatically adjusted by caredose software according to human anatomy and tissue density; the rotation time was 0.5 s, the pitch was 0.6, the layer thickness was 1.0 mm, the layer interval was 0.5 mm, the matrix was 512 × 512, and the lung and mediastinal windows were set as before.

Nine patients (mean age ± SD, 50.2 ± 7.0 years; age range, 41–63 years) with a clinical diagnosis of breast cancer were enrolled in the study between May 2017 and July 2017. All patients underwent whole-body PET/CT scan with 16α-[¹⁸F]FES before surgery. Patients underwent the surgical operation within 1 month after the PET/CT scan, and definitive diagnosis was determined using postoperative pathohistology analysis. The study protocol was approved by the Sichuan Cancer Hospital Ethics Committee, and informed consent was obtained from all patients before the PET/CT scan.
All patients fasted 4 h before FES-PET. Approximately a dose of 148–222 MBq (4–6 mCi) 16α-[¹⁸F]FES was infused intravenously over 2 min. The whole-body scanning (2 min per table position) was performed 1 h after administration using a Siemens Biograph mCT-64 PET/CT scanner.